Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ernexa Therapeutics Inc. ERNA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Ernexa Therapeutics Inc. (ERNA) is a Biotechnology company in the Healthcare sector, currently trading at $0.19. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: ERNA trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Net income is $14M (loss), growing at -8.5%/yr. Net profit margin is 0% (thin). Gross margin is 83.5% (+330.6 pp trend).

Balance sheet: total debt is $490,000 against $2M equity (Debt-to-Equity (D/E) ratio 0.2, conservative). Current ratio is 1.01 (adequate). Debt-to-assets is 8.4%. Total assets: $6M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 50/100 (Partial), Future ?/100 (Fail), Income ?/100 (Fail).

ERNA SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ERNA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
ERNA: +327.9%/yr revenue is, -8.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ERNA: Debt-to-Equity (D/E) ratio 0.2 (conservative), Current ratio is 1.01 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
ERNA: Gross margin is 83.5% (+330.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.18-4.05
Volume1.47M
Avg Volume (30D)1.73M
Market Cap$1.49M
Beta (1Y)6.85
Share Statistics
EPS (TTM)-2.24
Shares Outstanding$6.31M
IPO Date1991-08-29
Employees6
CEOSanjeev Luther
Financial Highlights & Ratios
Gross Profit$-263K
EBITDA$-9.06M
Net Income$-14.1M
Operating Income$-9.32M
Total Cash$1.88M
Total Debt$490K
Net Debt$-1.39M
Total Assets$5.83M
Price / Earnings (P/E)-0.1
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS1140823089

Price Chart

Track all markets on TradingView
ERNA
Ernexa Therapeutics Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.18 52WK RANGE 4.05

People Also View

APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
-0.01%
 GPCR
GPCR
Structure Therapeutics Inc.
$54.25
+1.94%
 RLAY
RLAY
Relay Therapeutics, Inc.
$15.49
+5.02%
 RCUS
RCUS
Arcus Biosciences, Inc.
$23.70
+3.00%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.95
+4.18%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message